Evidence map›Paper›PMID 23578728›Full record

ArticleAntiviral research2013

Repeated exposure to 5D9, an inhibitor of 3D polymerase, effectively limits the replication of foot-and-mouth disease virus in host cells.

Devendra K Rai, Elizabeth A Schafer, Kamalendra Singh, Mark A McIntosh, Stefan G Sarafianos, Elizabeth Rieder

Open access · greenAbstract read
In one paragraph

Article in Antiviral research, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
2.8field-weighted citation impact, top 11% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 11 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 3 institutions in 1 country.

Devendra K RaiForeign Animal Disease Research Unit, United States Department of Agriculture, Agricultural Research Service, Plum Island Animal Disease Center, Greenport, NY 11944-0848, USA.
Elizabeth A Schafer
Kamalendra Singh
Mark A McIntosh
Stefan G Sarafianos
Elizabeth Rieder
University of Missouri · USUnited States Department of Agriculture · USPlum Island Animal Disease Center · US

Funding

Ultrapotent Inhibitors of Wild-type and Multi-drug Resistant HIVR01AI076119 · NIAID · UNIVERSITY OF MISSOURI-COLUMBIA · PI SARAFIANOS, STEFAN G · 2008 to 2018
$4.1M
Hepatitis C antivirals: Mechanism of action, combination efficacy and resistanceR01AI099284 · NIAID · ROCKEFELLER UNIVERSITY · PI RICE, CHARLES M · 2012 to 2016
$3.6M
Ultrapotent Inhibitors of Wild-type and Multi-drug Resistant HIVR37AI076119 · NIAID · EMORY UNIVERSITY · PI Stefan G Sarafianos · 2020 to 2026
$3.6M
Novel antivirals targeting the RNase H activity of HIV reverse transcriptaseR01AI100890 · NIAID · UNIVERSITY OF MISSOURI-COLUMBIA · PI SARAFIANOS, STEFAN G, WANG, ZHENGQIANG · 2012 to 2016
$3.6M
NIAID NIH HHS AI076119NIAID NIH HHS AI099284NIAID NIH HHS AI100890NIAID NIH HHS R01 AI076119NIAID NIH HHS R01 AI099284NIAID NIH HHS R01 AI100890NIAID NIH HHS R37 AI076119
6 · The paper itself

Abstract

Foot-and-mouth disease (FMD) is a highly contagious disease of livestock caused by a highly variable RNA virus (FMDV) that has seven serotypes and more than sixty subtypes. Both prophylactic and post-infection means of controlling the disease outbreak, including universally applicable vaccines and emergency response measures such as therapeutic treatments, are on high demand. In this study, we analyzed the long-term exposure outcome to a previously identified inhibitor of 3D polymerase (FMDV 3Dpol) for controlling FMDV infection and for the selection of resistance mutants. The results showed that no escape mutant viruses were isolated from FMDV A24 Cruzeiro infections in cell culture treated with gradually increasing concentrations of the antiviral compound 5D9 (4-chloro-N'-thieno, [2,3-d]pyrimidin-4-ylbenzenesulfonohydrazide) over ten passages. Biochemical and plaque assays revealed that when 5D9 was used at concentrations within a non-toxic range in cells, it drove the virus to undetectable levels at passage eight to ten. This is in contrast with observations made on parallel control (untreated) passages exhibiting fully viable and stable virus progenies. Collectively, the results demonstrated that under the experimental conditions, treatment with 5D9 does not confer a resistant phenotype and the virus is unable to evade the antiviral effect of the inhibitor. Further efforts using quantitative structure-property relationship (QSPR) based modifications of the 5D9 compound may result in the successful development of an effective in vivo antiviral drug targeting FMDV.

Indexed as

AnimalsAntigens, ViralAntiviral AgentsCell LineCricetinaeDose-Response Relationship, DrugDrug Evaluation, PreclinicalDrug Resistance, ViralFoot-and-Mouth Disease VirusHeterocyclic Compounds, 2-RingInhibitory Concentration 50Microbial ViabilityRibavirinSerial PassageSulfonamidesTime Factors4-chloro-N'-thieno(2,3-d)pyrimidin-4-ylbenzenesulfonohydrazideAntigens, ViralAntiviral AgentsHeterocyclic Compounds, 2-RingRibavirinSulfonamidesViral Nonstructural Proteinsvirus-infection-associated antigen, Foot-and-mouth disease virus

Identifiers

PMID23578728
PMCPMC4141565
OpenAlexW2030512217

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.